Skye Biologics

Executive Summary

Skye Biologics is a private biotech company headquartered in San Diego, focused on discovering and developing breakthrough therapeutics that address the age-related decline in the body's natural repair and remodeling processes. Founded in 2010, the company employs innovative science to hack and optimize the healing loop, aiming to achieve organized advanced healing with minimal scarring, complications, failure, or re-injury. Targeting the biologics and oncology sectors, Skye Biologics seeks to restore the body's ability to repair damaged tissue, which becomes increasingly compromised with aging. By leveraging mechanisms that enhance functional tissue regeneration, the company's platform holds potential for applications in wound healing, surgical recovery, and oncology-related tissue damage. Although specific financial and pipeline details are not publicly disclosed, Skye Biologics operates in a high-need area of regenerative medicine and has the potential to address significant unmet medical needs across multiple therapeutic indications.

Upcoming Catalysts (preview)

• TBDAdvancement of lead therapeutic candidate into preclinical proof-of-concept studies60% success
• TBDPotential strategic partnership or licensing deal for wound healing or oncology indications45% success
• TBDSeries A or follow-on financing round to support clinical development50% success